RxDoctor Payments Data

Milton Haber

Internal Medicine · Laredo, TXNPI 1205983202

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Pfizer accounts for 83.7% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in TX, where the typical reported total is $270.

$76in general payments, 2019–2025

Across 4 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$64
  • Merck$12
$10,715,866in research payments, 2019–2025

Across 747 payments — averaging $14,345 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$9.4M
  • Pfizer$1.3M
  • Gilead$23K
  • Novo Nordisk AS$19K
  • Merck$9K

What the payments were for

  • Food & beverage$76100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer3$64
Merck1$12

How this compares

$76 in reported general payments places this provider in the 25th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Other internal medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →